Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis

Stephen B. Solomon, A. Semih Dogan, Theresa L. Nicol, James N Campbell, Martin Gilbert Pomper

Research output: Contribution to journalArticle

Abstract

Benign neurofibromas undergo sarcomatous transformation in approximately 5% of patients with neurofibromatosis type I. The clinical and radiologic diagnosis of sarcomatous change remains difficult. Positron emission tomography with F-18 fluorodeoxyglucose is a method to assess increased glucose metabolism in malignant tissue such as sarcomas. In this case report, positron emission tomography accurately distinguished malignant from benign neurofibromas. The technique may be useful as a noninvasive screening tool for malignant transformation of neurofibromas.

Original languageEnglish (US)
Pages (from-to)525-528
Number of pages4
JournalClinical Nuclear Medicine
Volume26
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Neurofibroma
Neurofibromatoses
Positron-Emission Tomography
Neurofibromatosis 1
Fluorodeoxyglucose F18
Sarcoma
Glucose

Keywords

  • F-18 Fluorodeoxyglucose
  • Malignant Degeneration
  • Neurofibromatosis
  • Positron Emission Tomography
  • Sarcoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis. / Solomon, Stephen B.; Semih Dogan, A.; Nicol, Theresa L.; Campbell, James N; Pomper, Martin Gilbert.

In: Clinical Nuclear Medicine, Vol. 26, No. 6, 2001, p. 525-528.

Research output: Contribution to journalArticle

@article{60ce962214aa4e82b3566df43eb20216,
title = "Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis",
abstract = "Benign neurofibromas undergo sarcomatous transformation in approximately 5{\%} of patients with neurofibromatosis type I. The clinical and radiologic diagnosis of sarcomatous change remains difficult. Positron emission tomography with F-18 fluorodeoxyglucose is a method to assess increased glucose metabolism in malignant tissue such as sarcomas. In this case report, positron emission tomography accurately distinguished malignant from benign neurofibromas. The technique may be useful as a noninvasive screening tool for malignant transformation of neurofibromas.",
keywords = "F-18 Fluorodeoxyglucose, Malignant Degeneration, Neurofibromatosis, Positron Emission Tomography, Sarcoma",
author = "Solomon, {Stephen B.} and {Semih Dogan}, A. and Nicol, {Theresa L.} and Campbell, {James N} and Pomper, {Martin Gilbert}",
year = "2001",
doi = "10.1097/00003072-200106000-00009",
language = "English (US)",
volume = "26",
pages = "525--528",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis

AU - Solomon, Stephen B.

AU - Semih Dogan, A.

AU - Nicol, Theresa L.

AU - Campbell, James N

AU - Pomper, Martin Gilbert

PY - 2001

Y1 - 2001

N2 - Benign neurofibromas undergo sarcomatous transformation in approximately 5% of patients with neurofibromatosis type I. The clinical and radiologic diagnosis of sarcomatous change remains difficult. Positron emission tomography with F-18 fluorodeoxyglucose is a method to assess increased glucose metabolism in malignant tissue such as sarcomas. In this case report, positron emission tomography accurately distinguished malignant from benign neurofibromas. The technique may be useful as a noninvasive screening tool for malignant transformation of neurofibromas.

AB - Benign neurofibromas undergo sarcomatous transformation in approximately 5% of patients with neurofibromatosis type I. The clinical and radiologic diagnosis of sarcomatous change remains difficult. Positron emission tomography with F-18 fluorodeoxyglucose is a method to assess increased glucose metabolism in malignant tissue such as sarcomas. In this case report, positron emission tomography accurately distinguished malignant from benign neurofibromas. The technique may be useful as a noninvasive screening tool for malignant transformation of neurofibromas.

KW - F-18 Fluorodeoxyglucose

KW - Malignant Degeneration

KW - Neurofibromatosis

KW - Positron Emission Tomography

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0035041472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035041472&partnerID=8YFLogxK

U2 - 10.1097/00003072-200106000-00009

DO - 10.1097/00003072-200106000-00009

M3 - Article

C2 - 11353300

AN - SCOPUS:0035041472

VL - 26

SP - 525

EP - 528

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 6

ER -